NO20044903L - Anvendelse av nye etonogestrel estere - Google Patents

Anvendelse av nye etonogestrel estere

Info

Publication number
NO20044903L
NO20044903L NO20044903A NO20044903A NO20044903L NO 20044903 L NO20044903 L NO 20044903L NO 20044903 A NO20044903 A NO 20044903A NO 20044903 A NO20044903 A NO 20044903A NO 20044903 L NO20044903 L NO 20044903L
Authority
NO
Norway
Prior art keywords
new
etonogestrel esters
contraceptive
esters
new etonogestrel
Prior art date
Application number
NO20044903A
Other languages
English (en)
Inventor
Hendrikus Adrianus Anton Voort
Dirk Leysen
Arij Jan Grootenhuis
Henrik De Nijs
Jaap Van Der Louw
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20044903L publication Critical patent/NO20044903L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer et prevensjonsmiddel- og/eller HRT-sett omfattende en kontraseptivt og/eller terapeutisk effektiv mengde av en langtidsvirkende etonogestrel-ester med en fettkjedelengde på C7-C15.
NO20044903A 2002-05-30 2004-11-10 Anvendelse av nye etonogestrel estere NO20044903L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30
PCT/EP2003/050188 WO2003101374A2 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters

Publications (1)

Publication Number Publication Date
NO20044903L true NO20044903L (no) 2005-02-25

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044903A NO20044903L (no) 2002-05-30 2004-11-10 Anvendelse av nye etonogestrel estere

Country Status (26)

Country Link
US (1) US20050222114A1 (no)
EP (1) EP1513588B1 (no)
JP (1) JP2005532336A (no)
KR (1) KR20050005507A (no)
CN (1) CN1655848A (no)
AR (1) AR040129A1 (no)
AT (1) ATE394140T1 (no)
AU (1) AU2003246740B2 (no)
BR (1) BR0311248A (no)
CA (1) CA2487293A1 (no)
DE (1) DE60320786D1 (no)
ES (1) ES2305498T3 (no)
HR (1) HRP20041127A2 (no)
IL (1) IL165125A0 (no)
IS (1) IS7537A (no)
MX (1) MXPA04011798A (no)
NO (1) NO20044903L (no)
NZ (1) NZ536618A (no)
PE (1) PE20040042A1 (no)
PL (1) PL373295A1 (no)
RS (1) RS101004A (no)
RU (1) RU2322986C2 (no)
TW (1) TW200400041A (no)
UA (1) UA80703C2 (no)
WO (1) WO2003101374A2 (no)
ZA (1) ZA200409498B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
MX2020003470A (es) * 2017-10-19 2020-10-01 Evestra Inc Anticonceptivos de profarmacos de progestina de accion mas prolongada.
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
CA3184810A1 (en) * 2020-06-11 2021-12-16 Ash Stevens, Llc Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
FI962618A7 (fi) * 1993-12-27 1996-06-25 Akzo Nobel Nv Perkutaanisesti absorboituva valmiste
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
RU2216546C2 (ru) * 1998-06-19 2003-11-20 Акцо Нобель Н.В. СОЕДИНЕНИЕ (7α,17β)-7-МЕТИЛ-17-[(1-ОКСОУНДЕЦИЛ)ОКСИ]ЭСТР-4-ЕН-3-ОН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, НАБОР ДЛЯ МУЖСКОЙ КОНТРАЦЕПЦИИ
AU4513099A (en) * 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Also Published As

Publication number Publication date
IS7537A (is) 2004-11-18
CN1655848A (zh) 2005-08-17
MXPA04011798A (es) 2005-03-31
KR20050005507A (ko) 2005-01-13
UA80703C2 (en) 2007-10-25
TW200400041A (en) 2004-01-01
ES2305498T3 (es) 2008-11-01
DE60320786D1 (de) 2008-06-19
CA2487293A1 (en) 2003-12-11
BR0311248A (pt) 2005-03-15
PE20040042A1 (es) 2004-01-31
RS101004A (sr) 2006-10-27
ATE394140T1 (de) 2008-05-15
HK1072568A1 (en) 2005-09-02
IL165125A0 (en) 2005-12-18
NZ536618A (en) 2007-06-29
WO2003101374A3 (en) 2004-02-26
WO2003101374A2 (en) 2003-12-11
HRP20041127A2 (en) 2005-02-28
AR040129A1 (es) 2005-03-16
JP2005532336A (ja) 2005-10-27
EP1513588A2 (en) 2005-03-16
US20050222114A1 (en) 2005-10-06
AU2003246740A1 (en) 2003-12-19
ZA200409498B (en) 2006-05-31
PL373295A1 (en) 2005-08-22
RU2004138809A (ru) 2005-06-10
EP1513588B1 (en) 2008-05-07
AU2003246740B2 (en) 2009-01-08
RU2322986C2 (ru) 2008-04-27

Similar Documents

Publication Publication Date Title
EP1512396A4 (en) HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
EE200400024A (et) Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
DK1490463T3 (da) Lav-transfedtsyrer til konfekture og fedtsammensætninger til bagning
DK1187613T3 (da) Amidsubstituerede imidazoquinoliner
SE9802333D0 (sv) Novel combination
EP1246621A4 (en) NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
NO20022988L (no) Vedvarende frigivelse (med dybdevirkning) av syklooksygenase- 2-inhibitor
NO20041872L (no) Esterforbindelser og medisinsk anvendelse derav
NO20020770L (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av obesitas
LU93072I2 (fr) Inhibiteur de la protéinase alpha-1 humaine
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
EP1569684A4 (en) USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20041272L (no) Tetracycline derivatives and methods of use thereof
CY2009001I1 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
IS2421B (is) Nýir etónógestrel esterar
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
EP1487776A4 (en) ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
NO20035318D0 (no) Farmasöytisk sammensetning omfattende en lipaseinhibitor og en sukrose fettsyreester
WO2003101374A3 (en) Use of new etonogestrel esters
EP1534293A4 (en) INFLAMMATORY COMPOSITIONS AND METHODS OF ADMINISTRATION
DE60317214D1 (de) Kristallines gamma-lacton der17beta-hydroxy-7alpha-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carbonsäure
NO20014444D0 (no) Topisk appliserbare bioadhesive preparater samt fremgangsmåter for anvendelse og fremstilling derav
AU2003291634A8 (en) Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
NO20032054L (no) Fettsyreanaloger for behandling av inflammatoriske lidelser og autoimmune forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application